Why is Injective price up 9.7% today?

Traders Union
All News
Crypto
Injective surges 9.75% today on gains

Highlights

Injective advanced institutional adoption with the Veyra mainnet vote, adding real-world asset support, cross-chain features, and future privacy groundwork.
The new Canary Staked INJ ETF debuted on Nasdaq, allowing US investors regulated access to INJ with most holdings staked for network rewards.
INJ trades with upward momentum above major moving averages and an expected five-day range of $7.42 to $8.62, but most technical indicators remain neutral.

Staking-focused ETF and governance upgrade boost investor engagement

Injective has advanced key institutional and ecosystem initiatives, including launching community voting for the Veyra mainnet upgrade proposal, which introduces institutional-grade real-world asset support, cross-chain features, and groundwork for privacy functions. Voting eligibility is limited to staked token holders, with over 13 million INJ already participating and initial support above 60%. Additionally, the new Canary Staked INJ ETF was launched on Nasdaq, providing US investors access to INJ through a regulated vehicle with most holdings staked for network rewards.

Anton Kharitonov, expert at Traders Union, believes INJ's recent surge is vulnerable given the weak technical momentum and dominant intraday selling. He notes that despite INJ trading above key moving averages, indicators like MACD, ADX, and RSI remain neutral, with bull/bear power favoring the bears. The analyst is cautious about the sustainability of gains since institutional news does not offset the risk of a reversal below $7.94. He also notes that the upcoming privacy and real-world asset features may take time to materialize in price action. “I see downside risks prevailing here despite the positive headlines and would advise caution near these highs.”

Viktoras Karapetjanc, expert at Traders Union, sees renewed strength in INJ supported by institutional demand and the Nasdaq ETF launch. He highlights the robust ecosystem progress, especially with community engagement around the Veyra upgrade. The bullish structure remains intact above major averages, and network fundamentals point to further adoption. “With strong fundamentals and institutional backing, I expect continued upward momentum for INJ in the near term.”

Sholanke Dele, market strategist, notes that INJ's recent gains are clouded by high volatility and lack of clear momentum signals. He sees risk in the elevated session highs alongside mixed macro drivers and uncertain sentiment. The analyst warns that the projected volatility band may trigger sudden downside moves, regardless of positive news. “I remain wary of chasing this rally until conviction and trend clarity clearly improve.”

Mixed momentum as price tests resistance in volatile trade

INJ/USD is trading above its 20-day, 50-day, and 200-day moving averages at $7.74, $7.82, and $5.77 respectively, highlighting bullish momentum across short, medium, and long timeframes. The near-term resistance is set by the Ichimoku Kijun at $8.12, while immediate support lies at $7.94. Momentum indicators present mixed signals; MACD and ADX are neutral, as are the RSI, Stochastic RSI, and CCI, suggesting no strong directional momentum. Bull/Bear Power shows sellers holding the edge intraday. Price action is close to today's highs amid high intraday volatility of 11.20%, with a daily gain to $8.02 representing a 9.75% increase and a 2.19% upside gap.

Previously it was reported that Injective's price action was supported by technical strength and anticipation surrounding governance votes and major protocol upgrades. The current analysis adds a new dimension with the launch of a staked ETF on Nasdaq, introducing a regulated access point for US investors and underscoring $8.12 as a pivotal level to watch for potential breakout or reversal.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.